|
125
|
| 449 |
SNCA
|
|
increases_quantity of
|
Ca2+
|
in mitochondria; if SNCA is overexpressed
|
|
18322646
|
Parkinson disease
|
|
248
|
| 1022 |
Ca2+
|
|
affects_activity of
|
S100A6-S100B complex
|
|
|
10913138
|
Metabolic
Epilepsy, temporal lobe
|
|
441
|
| 13796 |
Glutamate
|
|
increases_quantity of
|
Ca2+
|
in epileptic neurons
|
|
11587552
|
Epilepsy
|
|
449
|
| 1982 |
Ca2+
|
|
increases_activity of
|
abnormal excitatory postsynaptic currents
|
in pilocarpine model
|
|
11283235
|
Status epilepticus
Epilepsy, temporal lobe
|
|
545
|
| 2768 |
Ca2+
|
|
affects_quantity of
|
GSK3B (truncated)
|
via GSK3 proteolysis
|
|
19661623
|
Alzheimer disease
|
|
575
|
| 3036 |
Ca2+
|
|
affects_activity of
|
AMPK
|
|
|
16054096
|
Diabetes mellitus, type II
Insulin resistance
|
|
616
|
| 3273 |
Pilocarpine
|
|
increases_quantity of
|
Ca2+
|
in the pilocarpine model of temporal lobe epilepsy
|
|
11382382
|
Epilepsy, temporal lobe
|
|
683
|
| 3786 |
PSEN2-p.N141I
|
|
increases_quantity of
|
Ca2+
|
intracellular
|
|
16394273
|
Alzheimer disease
|
|
687
|
| 3741 |
Ca2+
|
|
affects_activity of
|
increased susceptibility to neuronal excitotoxicity
|
|
|
7491714
|
Status epilepticus
|
|
831
|
| 4927 |
Ca2+
|
|
increases_activity of
|
PPP3CB
|
|
|
14744247
|
Schizophrenia
|
|
832
|
| 4937 |
Ca2+
|
|
interacts (colocalizes) with
|
CALM1
|
|
| 59106 |
Ca2+
|
|
increases_activity of
|
Calcium/calmodulin-dependent protein kinase type II
|
|
|
11931644
|
Neurological
Schizophrenia
|
|
1,125
|
| 7270 |
NMDA receptor complex
|
|
increases_quantity of
|
Ca2+
|
|
| 7271 |
Ca2+
|
|
increases_activity of
|
convulsive seizures
|
|
|
19775068
|
Epilepsy
|
|
1,348
|
| 9214 |
Ca2+
|
|
affects_activity of
|
neurotransmitter secretion
|
|
|
19641596
|
Alzheimer disease
|
|
1,427
|
| 9938 |
PINK1
|
|
affects_quantity of
|
Ca2+
|
|
| 9940 |
Ca2+
|
|
affects_activity of
|
mitochondrial depolarization
|
|
| 9945 |
PINK1
|
|
affects transport of
|
Ca2+
|
in mitochondrial
|
|
19285945
|
Parkinson disease
|
|
1,459
|
| 10309 |
SOD1-p.G93A
|
|
increases_quantity of
|
Ca2+
|
in cytosol
|
|
19889637
|
Amyotrophic lateral sclerosis
|
|
1,548
|
| 11061 |
Ca2+
|
|
increases_activity of
|
inflammatory response
|
|
| 11069 |
purinergic receptor signaling pathway
|
|
increases_quantity of
|
Ca2+
|
in microglia cells
|
| 11070 |
calcium-mediated signaling using extracellular calcium source
|
|
increases_quantity of
|
Ca2+
|
in microglia cells
|
| 11071 |
Mg2+
|
|
decreases_quantity of
|
Ca2+
|
in microglia cells
|
|
21040713
|
Parkinson disease
|
|
1,556
|
| 11111 |
CALHM1
|
|
affects_quantity of
|
Ca2+
|
|
|
18585350
|
Alzheimer disease
|
|
1,660
|
| 12295 |
Schizophrenia
|
|
increases_quantity of
|
Ca2+
|
in peripheral blood cells
|
|
20833242
|
Schizophrenia
|
|
1,752
|
| 13178 |
SOD1-p.G93A
|
|
increases_quantity of
|
Ca2+
|
in motor neurons
|
|
17099894
|
Amyotrophic lateral sclerosis
|
|
1,914
|
| 14857 |
Buthionine sulfoximine
|
|
increases_quantity of
|
Ca2+
|
in microglia and astrocytes
|
| 14859 |
Clotrimazole
|
|
decreases_quantity of
|
Ca2+
|
|
|
20228251
|
Alzheimer disease
|
|
2,029
|
| 16110 |
Bipolar disorder
|
|
increases_quantity of
|
Ca2+
|
|
|
1728159
|
Bipolar disorder
|
|
2,138
|
| 17657 |
Sphingosylphosphorylcholine
|
|
increases_quantity of
|
Ca2+
|
|
| 17659 |
Sphingosine 1-phosphate
|
|
increases_quantity of
|
Ca2+
|
|
| 17660 |
Lysosulfatide
|
|
increases_quantity of
|
Ca2+
|
|
| 17676 |
S1PR3
|
|
affects_quantity of
|
Ca2+
|
if induced by HDL, SPC, S1P, or LSF
|
|
14966566
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,139
|
| 17715 |
Ca2+
|
|
increases_activity of
|
NOS3
|
|
|
10376603
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,272
|
| 19408 |
NNT
|
|
affects_quantity of
|
Ca2+
|
in pancreas
|
|
16399503
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,578
|
| 24275 |
Ca2+
|
|
increases_activity of
|
insulin secretion
|
in pancreas, in pancreatic beta cells
|
|
21968738
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,584
|
| 24343 |
XBP1
|
|
decreases_quantity of
|
Ca2+
|
in cytosol of PC12 cells treated with Abeta oligomers
|
|
21389082
|
Alzheimer disease
|
|
2,593
|
| 24463 |
Bepridil
|
|
decreases_activity of
|
Ca2+
|
|
| 24464 |
Amiodarone
|
|
decreases_activity of
|
Ca2+
|
|
|
20592218
|
Alzheimer disease
|
|
2,596
|
| 24526 |
Ca2+
|
|
affects_activity of
|
Phosphatidylinositol-4,5-bisphosphate 5-phosphatase
|
|
|
18391946
|
Alzheimer disease
|
|
3,012
|
| 27550 |
Ca2+
|
|
increases_activity of
|
Calcineurin
|
in T4C3 (TAU truncated at Asp-421 to mimic caspase cleavage) cells
|
|
19389700
|
Alzheimer disease
|
|
3,040
|
| 27970 |
Dexamethasone
|
NOT |
affects_quantity of
|
Ca2+
|
in cytoplasm, in pancreas, in pancreatic beta cells
|
| 27971 |
Dexamethasone
|
|
decreases_activity of
|
Ca2+
|
in cytoplasm, in pancreas, in pancreatic beta cells
|
| 27972 |
Ca2+
|
|
increases_activity of
|
insulin secretion
|
in cytoplasm, in pancreas, in pancreatic beta cells
|
|
9022074
|
Diabetes mellitus, type II
Insulin resistance
Major depressive disorder
|
CIDeRplus